An evolving technology for an evolving disease: A commentary on NGS-based MRD evaluation in B-ALL

The ability to detect “minimal residual disease” (MRD) is profoundly impacting the treatment approach to acute lymphoblastic leukemia (ALL). While several MRD assays are available, including flow cytometry and targeted PCR, “high throughput sequencing” (HTS) or next generation sequencing (NGS) methods appear part icularly promising. One of these approaches – the Adaptive Biotechnologies clonoSEQ® assay – was recently granted FDA approval. No published trial tells us what to do with knowledge of NGS-based MRD status, but clearly this is the next step.

Source: Leukemia Research - November 16, 2018 Category: Hematology Authors: Carol Fries, Richard Burack Tags: Commentary Source Type: research